X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (297) 297
humans (273) 273
infectious diseases (223) 223
hiv infections - drug therapy (195) 195
hiv (154) 154
male (148) 148
antiretroviral-naive adults (143) 143
adult (142) 142
female (141) 141
pharmacology & pharmacy (127) 127
immunology (122) 122
once-daily dolutegravir (120) 120
double-blind (110) 110
middle aged (103) 103
hiv infections - virology (101) 101
anti-hiv agents - therapeutic use (92) 92
hiv-1 - drug effects (90) 90
human immunodeficiency virus--hiv (89) 89
virology (89) 89
raltegravir (86) 86
antiretroviral-naive (83) 83
therapy (82) 82
microbiology (80) 80
antiretroviral drugs (72) 72
antiretroviral-naive patients (72) 72
aids/hiv (70) 70
hiv infection (68) 68
tenofovir (65) 65
dolutegravir (64) 64
drug therapy (62) 62
hiv-1 - genetics (58) 58
anti-hiv agents - adverse effects (57) 57
antiretroviral therapy (56) 56
antiviral agents (56) 56
drug resistance (55) 55
mutation (54) 54
viral load (53) 53
anti-hiv agents - administration & dosage (52) 52
infection (52) 52
protease inhibitors (48) 48
treatment outcome (48) 48
hiv-1 infection (47) 47
drug resistance, viral (45) 45
aids (43) 43
hiv-1 (43) 43
pharmacokinetics (43) 43
emtricitabine (42) 42
safety (42) 42
cd4 lymphocyte count (41) 41
initial treatment (41) 41
lamivudine (41) 41
young adult (41) 41
hiv-1-infected patients (39) 39
efavirenz (38) 38
anti-hiv agents - pharmacology (37) 37
efficacy (37) 37
human-immunodeficiency-virus (37) 37
non-inferiority trial (37) 37
analysis (36) 36
research (36) 36
resistance (36) 36
tenofovir disoproxil fumarate (36) 36
drug resistance, viral - genetics (35) 35
adolescent (34) 34
clinical trials (34) 34
heterocyclic compounds, 3-ring - therapeutic use (34) 34
hiv integrase inhibitors - therapeutic use (34) 34
prevalence (34) 34
adenine - analogs & derivatives (33) 33
highly active antiretroviral therapy (33) 33
antiretroviral naive (31) 31
drug therapy, combination (30) 30
hiv-infected patients (30) 30
open-label (30) 30
reverse transcriptase inhibitors - therapeutic use (30) 30
hiv integrase inhibitors - pharmacology (29) 29
integrase (29) 29
patients (29) 29
antiretroviral agents (28) 28
heterocyclic compounds, 3-ring - administration & dosage (28) 28
infected patients (28) 28
reverse-transcriptase inhibitors (28) 28
abacavir (27) 27
co-formulated elvitegravir (27) 27
drug-resistance (27) 27
heterocyclic compounds, 3-ring - adverse effects (27) 27
hiv infections - epidemiology (27) 27
risk factors (27) 27
genotype (26) 26
health aspects (26) 26
heterocyclic compounds, 3-ring - pharmacology (26) 26
hiv-1 - isolation & purification (26) 26
human immunodeficiency virus (26) 26
rna, viral - blood (26) 26
aged (25) 25
antiretroviral therapy, highly active (25) 25
dosage and administration (25) 25
lamivudine - therapeutic use (25) 25
acquired immune deficiency syndrome--aids (24) 24
elvitegravir (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 12/2006, Volume 43, Issue 5, pp. 535 - 540
Background: in antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes... 
larnivudine | ABACAVIR | emtricitabine | INFECTIOUS DISEASES | lipoatrophy | zidovudine | tenofovir | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | PREDICTION | SERUM CREATININE | LAMIVUDINE | antiretroviral naive | HIV-INFECTION
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 06/2017, Volume 75, Issue 2, pp. 226 - 231
In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs.... 
osteopenia | ANTIRETROVIRAL-NAIVE | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | ELVITEGRAVIR | proteinuria | COBICISTAT | EMTRICITABINE | IMMUNOLOGY | DENSITY | HIV | EFAVIRENZ | DOUBLE-BLIND | ABACAVIR/LAMIVUDINE | tenofovir alafenamide | TENOFOVIR/EMTRICITABINE
Journal Article
Antiviral Therapy, ISSN 1359-6535, 2017, Volume 22, Issue 4, pp. 295 - 305
Background: Simplified dosing regimens are important for patients who face challenges in adhering to HIV-1 therapy. We investigated the safety and virological... 
INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | EFFICACY | TRIAL | LAMIVUDINE | VIROLOGY | DOUBLE-BLIND | SPRING-2 | PHARMACOLOGY & PHARMACY | HIV-1 INFECTION | INTEGRASE INHIBITOR | ANTIRETROVIRAL-NAIVE ADULTS
Journal Article
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 03/2019, Volume 74, Issue 3, pp. 739 - 745
Abstract Objectives To evaluate the dolutegravir+lamivudine combination in virologically suppressed patients living with HIV. Methods The ANRS 167 LAMIDOL... 
INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | EFFICACY | SAFETY | MICROBIOLOGY | OPEN-LABEL | HIV-1-INFECTED PATIENTS | 48-WEEK | NON-INFERIORITY | PHARMACOLOGY & PHARMACY | INFECTION | RILPIVIRINE | ANTIRETROVIRAL-NAIVE ADULTS
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2018, Volume 67, Issue 5, pp. 791 - 794
Abstract Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing... 
antiretroviral therapy | integrase strand transfer inhibitors | drug resistance | INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | DOUBLE-BLIND | MICROBIOLOGY | IMMUNOLOGY | HIV-1 INFECTION | ANTIRETROVIRAL-NAIVE ADULTS | Brief Reports
Journal Article
The Journal of antimicrobial chemotherapy, ISSN 0305-7453, 01/2019, Volume 74, Issue 5, pp. 1363 - 1367
To evaluate the durability of three integrase strand transfer inhibitors (INSTIs) and two NRTIs in ART-naive individuals. The study design was observational.... 
INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | EMTRICITABINE | MICROBIOLOGY | DISCONTINUATION | THERAPY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HIV-1 INFECTION | ADVERSE EVENTS | TENOFOVIR | ANTIRETROVIRAL-NAIVE ADULTS
Journal Article
AIDS research and human retroviruses, ISSN 0889-2229, 02/2019, Volume 35, Issue 2, pp. 150 - 154
Access to nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART)... 
antiretroviral-naive | pre-ART HIV drug resistant | HIV | oligonucleotide ligation assay | Peru | INFECTIOUS DISEASES | VIROLOGY | SURVEILLANCE | MUTATIONS | IMMUNOLOGY
Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 02/2019, Volume 80, Issue 2, pp. 242 - 245
Objective: To investigate the longitudinal changes of gut structural damage in chronically untreated HIV infection. Design: This is a 96-week prospective,... 
I-FABP | BARRIER DYSFUNCTION | INFECTIOUS DISEASES | EPITHELIAL BARRIER | ACTIVATION | PROTEIN | gut integrity | ADULTS | antiretroviral-naive | MEDIA THICKNESS PROGRESSION | IMMUNOLOGY | INFLAMMATION | DYSBIOSIS | PREDICT MORTALITY | MICROBIAL TRANSLOCATION
Journal Article
Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 11/2016, Volume 73, Issue 3, pp. 294 - 298
Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple... 
ANTIRETROVIRAL-NAIVE | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | elvitegravir | CHRONIC HEPATITIS-B | EMTRICITABINE | bone | IMMUNOLOGY | HIV-INFECTED PATIENTS | renal | DENSITY | TENOFOVIR DISOPROXIL FUMARATE | HIV | PHARMACOKINETICS | EFAVIRENZ | TAF | tenofovir alafenamide | HBV | coinfection
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 10/2016, Volume 73, Issue 2, pp. 177 - 181
Tenofovir disoproxil fumarate (TDF) can cause kidney damage, but current clinical tests are insensitive for detecting toxicity. Among 884 HIV-infected men... 
Biomarker | Nephrotoxicity | Kidney | Tenofovir disoproxil fumarate | ANTIRETROVIRAL-NAIVE | INFECTIOUS DISEASES | tenofovir disoproxil fumarate | IMMUNOLOGY | biomarker | URINARY | kidney | GLOMERULAR-FILTRATION-RATE | FUNCTION DECLINE | MOLECULE-1 KIM-1 | NECROSIS | nephrotoxicity | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | KIDNEY INJURY | RENAL TOXICITY
Journal Article
Journal Article